MDXXF Stock Chart & Stats
$0.11
<$0.01(6.31%)
At close: 4:00 PM EDT
$0.11
<$0.01(6.31%)
Day’s Range― - ―
52-Week Range$0.06 - $0.20
Previous CloseN/A
Volume100.00
Average Volume (3M)17.70K
Market Cap
$18.06M
Enterprise Value$18.29
Total Cash (Recent Filing)$245.06K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding109,236,030
10 Day Avg. Volume7,350
30 Day Avg. Volume17,697
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthRevenue growth indicates improving commercial traction and customer activity. Sustained expansion could provide operating leverage over time, although the current scale remains modest and further growth is needed to support a durable business model.
Debt-Free Balance SheetThe absence of reported debt limits interest burden and refinancing risk, while positive equity and assets provide some financial support. This gives the company more flexibility to fund development than a similarly loss-making business with leverage.
Margin Performance ImprovingImprovement from extremely negative prior-year margins suggests potential progress in cost control or product economics. If maintained alongside revenue growth, this could gradually reduce operating losses, though profitability has not yet been established.
Bears Say
Persistent Operating LossesNegative gross profit and substantial operating losses show that current revenue does not cover the cost structure. Continued losses could constrain investment, weaken equity over time, and delay the company’s path to self-sustaining operations.
Negative Free Cash FlowPersistent cash burn means operations are not yet funding themselves and external financing may remain necessary. Unless revenue scales materially or expenses decline, funding requirements could limit strategic flexibility and increase dilution risk.
High Cost StructureA high operating cost base relative to modest revenue makes earnings sensitive to execution and sales growth. Without meaningful operating leverage, additional revenue may not translate into sufficient profit or cash generation over the next several quarters.
PharmAla Biotech Holdings, Inc. News
MDXXF FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was $0.06 and its highest was $0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is $18.06M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Dec 18, 2026 which is in 110 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Jul 29, 2026. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 109,236,030 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.893%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in MDXXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.